Please login to the form below

Not currently logged in
Email:
Password:

Dr Ulf Jungnelius joins Oasmia Pharmaceuticals

He becomes senior medical advisor

Oasmia Pharmaceuticals Dr Ulf JungneliusOasmia Pharmaceuticals has appointed Dr Ulf Jungnelius as its new senior medical advisor.

He brings over 40 years of experience in oncology clinical research and development to the Uppsala, Sweden-based firm, having held leading positions in oncology at Eli Lilly, Pfizer and Takeda.

Most recently, Dr Jungnelius served as vice president, CR&D oncology at Celgene and continues serve as a partner for Healthcom, a healthcare technology company based in the US.

Julian Aleksov, executive chairman of Oasmia, said: “We are thrilled to add Dr Ulf Jungnelius, an individual with a very strong therapeutic area expertise and who has been a key driver in taking oncology blockbusters to regulatory approval and commercial success, to the Oasmia Pharmaceutical team.”

Meanwhile, Oasmia also announced Anders Lundin's resignation as chief financial officer.

Lundin joined the oncology drug developer in 2014, having previously served as head of finance at Galderma, a Swiss dermatology firm.

He will leave the company to pursue other business opportunities on 31 March.

5th February 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics